It has been reported that mutations in the PBRM1 gene resulted in melanoma cells being more sensitive to the T-cell-produced interferon IFN-γ and recruited more anti-tumor T-cells into the tumor periphery, resulting in increased therapeutic sensitivity to PD1 immune-surveillance point inhibitors 19. This evidence concerns the gene IFNG and melanoma.